Molecular and Cellular Immunology Core

分子和细胞免疫学核心

• 批准号: 10576206
• 负责人: George S Hui
• 金额: $ 19.35万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-14 至 2023-07-13
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576206
• 关键词: Affect; Africa; Asia; Back; Biomedical Research; Biotechnology; Burn injury; Businesses; Caliber; Cell Separation; Cellular Immunology; Centers of Research Excellence; Climate; Collaborations; Communities; Core Facility; Custom; Discipline; Effectiveness; Elements; Emerging Communicable Diseases; Ensure; Equipment; Evaluation; Extramural Activities; Fees; Flow Cytometry; Fostering; Funding; Goals; Grant; Hawaii; Health; Hospitals; Human Resources; Immunologics; Infectious Disease Immunology; Infectious Diseases Research; Infrastructure; Institution; International; Maintenance; Marketing; Mentors; Mission; Molecular Immunology; Monitor; Needs Assessment; Periodicity; Phase; Phase Transition; Principal Investigator; Productivity; Publications; Research; Research Infrastructure; Research Personnel; Research Training; Resource Allocation; Resources; Role; Schedule; Science; Scientific Inquiry; Scientist; Services; Stream; Structure; Surveys; System; Techniques; Training; Training Programs; Training and Education; Triad Acrylic Resin; Universities; base; effectiveness evaluation; improved; laboratory experience; medical schools; operation; outreach; programs; prospective; research and development; satisfaction; skills; success; tool

Project Summary for the Molecular and Cellular Immunology Core As the singular research resource for flow cytometry, cell sorting and myriad immunological services at the University of Hawaii (UH) and in the entire State of Hawaii, the Molecular and Cellular Immunology (MCI) Core has had a significant impact on increasing research productivity, enhancing research competitiveness and heightening grants success during COBRE Phases I and II. Extramurally funded research is heavily dependent on the MCI Core, and the need is anticipated to grow during and beyond the Phase III COBRE period. The Phase III COBRE objective of facilitating the transition of the MCI Core into a sustainable state-of-the-art core facility capable of supporting high-caliber research on new, emerging and re-emerging infectious diseases, as well as other fields of scientific inquiry, will be achieved by (1) enhancing and streamlining core operations; (2) growing and diversifying the user base, capability, capacity and reach; and (3) strengthening the core infrastructure. For Aim 1, needs assessments and user satisfaction surveys will be conducted to ensure efficiency and effectiveness of core operations. Also, mentoring and training of current and prospective users will be better integrated, and partnerships will be formed with research training programs in infectious diseases and immunology. For Aim 2, outreach and marketing activities will be expanded to other local academic institutions, biotech companies and hospitals beyond the UH System, and strong partnerships will be formed with similar cores located in other COBRE, INBRE and IDeA-CTR programs to grow and diversify the core user base and to acquire new tools and techniques. Also, the MCI Core will leverage the existing infrastructure of research training laboratories in the Asia-Pacific region to facilitate international collaborative research. And for Aim 3, sustainability and phased-in business plans will be developed during the Phase III COBRE period to draw on multiple avenues of intramural and extramural support to sustain the Core. Periodic evaluation and review of the Core's fiscal health will allow necessary restructuring of the key elements affecting solvency to guide efforts to sustain the Core beyond Phase III COBRE support. The MCI Core is expected to achieve each of the above-stated specific aims. A strong commitment of $50,000 per year for five years beyond the Phase III COBRE period, by the JABSOM Dean, will provide an important hedge against uncertain revenue streams during this competitive and uncertain funding climate and will ensure continued core operations, with the prospect of increased grants success and core sustainability.

分子和细胞免疫学核心项目摘要 作为流式细胞术、细胞分选和无数免疫学服务的单一研究资源 夏威夷大学 (UH) 和整个夏威夷州的分子和细胞免疫学 (MCI) 核心 对提高科研生产力、增强科研竞争力产生了重大影响 提高 COBRE 第一阶段和第二阶段赠款的成功率。外部资助的研究严重依赖 在 MCI 核心上，预计在第三阶段 COBRE 期间及之后需求将会增长。 COBRE 第三阶段的目标是促进 MCI 核心过渡到可持续的最先进技术 能够支持新的、正在出现的和重新出现的传染病的高水平研究的核心设施 疾病以及其他科学探究领域将通过以下方式实现：（1）加强和简化核心 运营; (2) 扩大用户基础、能力、能力和范围并使其多样化； (3) 加强 核心基础设施。对于目标 1，将进行需求评估和用户满意度调查 确保核心运营的效率和有效性。此外，对当前和未来的人员进行指导和培训 用户将得到更好的整合，并且将与传染病研究培训项目建立伙伴关系 疾病和免疫学。对于目标 2，外展和营销活动将扩展到其他当地 夏威夷大学系统以外的学术机构、生物技术公司和医院，以及强有力的合作伙伴关系将 由位于其他 COBRE、INBRE 和 IDeA-CTR 计划中的类似核心组成，以发展和多样化 核心用户群并获得新的工具和技术。此外，MCI Core 将利用现有的 亚太地区研究培训实验室基础设施，以促进国际合作 研究。对于目标 3，将在第三阶段制定可持续性和分阶段业务计划 COBRE 期间利用多种途径的校内和校外支持来维持核心。定期 对核心财政健康状况的评估和审查将有助于对影响核心的关键要素进行必要的重组 偿付能力，以指导在第三阶段 COBRE 支持之后维持核心的努力。 MCI 核心预计将实现上述每一个具体目标。 50,000 美元的坚定承诺 JABSOM 院长在第三阶段 COBRE 期之后的五年内每年将提供重要的 在这种竞争激烈且不确定的融资环境中对冲不确定的收入流，并将确保 继续开展核心业务，有望提高赠款成功率和核心可持续性。